Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Carbimazole
Advanz Pharma
H03BB01
Carbimazole
20mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 06020200; GTIN: 5060337260091
OBJECT 1 CARBIMAZOLE 20 MG TABLETS Summary of Product Characteristics Updated 20-Apr-2021 | ADVANZ Pharma • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Carbimazole 20 mg Tablets 2. Qualitative and quantitative composition Each tablet contains 20 mg of carbimazole. Excipients with known effect: Lactose Anhydrous (125.35 mg per tablet) For a full list of excipients see section 6.1. 3. Pharmaceutical form Pale pink, uncoated, round, biconvex tablets marked with LINK C20 on one side and a scoreline on the reverse. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. Clinical particulars 4.1 Therapeutic indications Carbimazole is an anti-thyroid agent. It is indicated in adults and children in all conditions where reduction of thyroid function is required. Such conditions are: 1. Hyperthyroidism. 2. Preparation for thyroidectomy in hyperthyroidism. 3. Therapy prior to and post radio-iodine treatment. 4.2 Posology and me Read the complete document